Loading stock data…
Lexicon Pharmaceuticals, Inc. (LXRX)
$2.23-0.01 (-0.45%)
Market ClosedLast close Sep 8
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Lexicon Pharmaceuticals, Inc. in the Healthcare sector is trading at $2.23 with a market capitalization of $1.0B. Wall Street consensus targets $3.86 (5 analysts), implying a +72.9% move over the next 12 months. The stock is currently 17% below its 52-week high of $2.68, remaining 24.6% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +72.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $692,000↓ | $21.10M↑ | $5.49M↓ | $14.18M↓ | $28.87M |
| Gross Profit | $653,000↓ | $20.99M↑ | $5.29M↓ | $14.17M↓ | $28.83M |
| Operating Income | -$26.54M↓ | -$996,000↑ | -$14.78M↓ | -$12.19M↓ | $3.74M |
| Net Income | -$31.77M↓ | -$1.04M↑ | -$15.53M↓ | -$12.77M↓ | $3.25M |
Peer Comparison
JNJUNHPFE
Fundamentals
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small mole...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.02B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.03
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-35.02%
Volume
Today's trading volume
1.65M
Recent News
LXRX Stock Edges Higher On $10M Payout From Novo Nordisk — Retail Traders Highlight More Cash Milestones On The Horizon
Lexicon announced the payment after Novo Nordisk hit a key patient-dosing target in the early-stage trial of LX9851.
Novo Nordisk (CPSE:NOVO B) Reaches LX9851 Obesity Drug Milestone
Novo Nordisk (CPSE:NOVO B) and Lexicon Pharmaceuticals reached a key milestone in the development of first in class oral obesity drug LX9851. Lexicon received a milestone payment from Novo Nordisk tied to clinical progress for LX9851 in obesity and metabolic disorders. The advancement of LX9851 adds a new mechanism of action to Novo Nordisk's obesity pipeline alongside its existing treatments. The update underscores ongoing efforts to address obesity as a major global health challenge with...
Lexicon (LXRX) Q2 2026 Earnings Call Transcript
SONATA-HCM Phase III enrollment topped 500 patients; data due Q1 2027.
Why Lexicon Pharmaceuticals (LXRX) Is Up 6.9% After Q2 Revenue Collapse And New Shelf Filings
In early August 2026, Lexicon Pharmaceuticals reported second-quarter results showing revenue of US$692,000 versus US$28.87 million a year earlier, alongside a shift from net income of US$3.25 million to a net loss of US$31.78 million and wider per-share losses. On the same day, the company filed two shelf registrations totaling about US$44.73 million in common stock capacity, highlighting both the strain on its current financial position and its intention to preserve flexibility for future...
Lexicon Pharmaceuticals Inc (LXRX) (Q2 2026) Earnings Call Highlights: Zynquista NDA ...
Lexicon Pharmaceuticals Inc (LXRX) advances its pipeline with strong cash position despite a challenging quarter marked by a net loss and reduced revenues.